## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 96/17994 (51) International Patent Classification 6: (11) International Publication Number: A1 D06M 16/00, C12N 9/42 13 June 1996 (13.06.96) (43) International Publication Date: (81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, PCT/DK95/00488 (21) International Application Number: CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, 5 December 1995 (05.12.95) (22) International Filing Date: MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, (30) Priority Data: MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, DK 5 December 1994 (05.12.94) 1387/94 GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd **Published** (DK). With international search report. (72) Inventors; and (75) Inventors/Applicants (for US only): LUND, Henrik [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). PEDERSEN, Hanne, Høst [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents. Novo Allé, DK-2880 Bagsværd (DK).

(54) Title: A METHOD OF OBTAINING A CELLULOSIC TEXTILE FABRIC WITH REDUCED TENDENCY TO PILLING FORMATION

#### (57) Abstract

A method for obtaining a cellulosic textile fabric having a strongly reduced tendency to pilling formation, preferably corresponding to a pilling note of at least 4, more preferably of at least 4.5, which method comprises treating the fabric with a cellulase capable of performing a partial hydrolysis of the fibre surface corresponding to a < 2 % weight loss based on the untreated cellulosic textile fabric. The cellulase is preferably a 43 kD endoglucanase derived from or producible by *Humicola insolens*, DSM 1800, SEQ ID NO:1, or a functional analogue of said cellulase such as a variant which is modified by substitution of one or more amino acid residues in one or more of the positions 8, 55, 58, 62, 67, 132, 147, 162, 221, 222, 223, 280; or modified by truncation, preferably genetically truncation, at any position from position 213.

**BEST AVAILABLE COPY** 

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|      | Austria                  | GB    | United Kingdom               | MR | Mauritania               |
|------|--------------------------|-------|------------------------------|----|--------------------------|
| AT   | Australia                | GE    | Georgia                      | MW | Malawi                   |
| AU   | Australia<br>Barbados    | GN    | Guinea                       | NE | Niger                    |
| BB   |                          | GR    | Greece                       | NL | Netherlands              |
| BE   | Belgium                  | HU    | Hungary                      | NO | Norway                   |
| BF   | Burkina Faso             |       | Ireland                      | NZ | New Zealand              |
| BG   | Bulgaria                 | IE    |                              | PL | Poland                   |
| BJ   | Benin                    | ΙT    | Italy                        | PT |                          |
| BR   | Brazil                   | JP    | labau                        |    | Portugal                 |
| BY   | Belanus                  | KE    | Kenya                        | RO | Romania                  |
| CA   | Canada                   | KG    | Kyrgystan                    | RU | Russian Federation       |
| CF   | Central African Republic | KP    | Democratic People's Republic | SD | Sudan                    |
| CG   | Congo                    |       | of Korea                     | SE | Sweden                   |
| СН   | Switzerland              | KR    | Republic of Korea            | SI | Slovenia                 |
| · CI | Côte d'Ivoire            | KZ    | Kazakhstan                   | SK | Slovakia                 |
| CM   | Cameroon                 | LI    | Liechtenstein                | SN | Senegal                  |
| CN   | China                    | LK    | Sri Lanka                    | TD | Chad                     |
| CS   | Czechoslovakia           | LU    | Luxembourg                   | TG | Togo                     |
| cz   | Czech Republic           | LV    | Larvia                       | TJ | Tajikistan               |
| DE   | Germany                  | MC    | Monaco                       | TT | Trinidad and Tobago      |
| DK   | Denmark                  | MD    | Republic of Moldova          | UA | Ukraine                  |
| ES   | Spain                    | MG    | Madagascar                   | US | United States of America |
| EI   | Finland                  | ML    | Mali                         | UZ | Uzbekistan               |
|      | France                   | MN    | Mongolia                     | VN | Viet Nam                 |
| FR   |                          | 14114 | Mongona                      |    |                          |
| GA   | Gabon                    |       |                              |    |                          |

1

A METHOD OF OBTAINING A CELLULOSIC TEXTILE FABRIC WITH REDU-CED TENDENCY TO PILLING FORMATION

The present invention relates to a method for obtaining a cellulosic textile fabric having a strongly reduced tendency 5 to pilling formation. More specifically, the invention relates to a method wherein the cellulosic textile fabric is subjected to an enzymatic treatment with a cellulase without substantial weight loss.

#### BACKGROUND OF THE INVENTION

10 Without the application of finishing components, most cotton fabrics and cotton blend fabrics have a handle appearance that is rather hard and stiff. The fabric surface also is not smooth because small fuzzy microfibrils protrude from it. In addition, after a relatively short period of wear, pilling 15 appears on the fabric surface thereby giving it an unappealing, worn look.

A known method for obtaining a soft and smooth fabric is to subject cellulosic fabrics to treatment by cellulolytic enzymes during their manufacture. This treatment is known as Bio-Polishing (hereinafter denoted biopolishing), cf. Bazin j. and Sasserod, S.: Enzymatic Bio-Polishing of Cellulosic Fabric, Paper presented on October 25th, 1991, at "58ème Congrès de l'Association des Chimistes de l'Industrie Textile", Mulhouse, France, which is hereby incorporated by reference.

25 Biopolishing is a specific treatment of the yarn surface which improves fabric quality with respect to handle and appearance without loss of fabric wettability. The most important effects of biopolishing can be characterised by less fuzz and pilling, increased gloss/luster, improved fabric 30 handle, increased durable softness and improved water absor-

bency.

Biopolishing usually takes place in the wet processing of the manufacture of knitted and woven fabrics. Wet processing comprises such steps as e.g. desizing, scouring, bleaching, washing, dying/printing and finishing. During each of these steps, the fabric can be subjected to mechanical action.

However, since the cellulolytic enzymes catalyse hydrolysis of the cellulosic fibre surface, the enzymatic action will eventually result in a weight loss of fibre or fabric. Even though the biopolishing is carried out in such a way so as to obtain a controlled, partial hydrolysis of the fibre surface, a proper polishing effect without excessive loss of fabric strength has hitherto been obtained at a weight loss of fabric of 3-5 w/w%. Such a weight loss is undesirable for the textile industry and, for economical reasons, makes the biopolishing process less desirable.

Thus, it is the object of the present invention to provide a method for obtaining a cellulosic textile fabric with strongly reduced tendency to pilling formation but without substantial weight loss of fabric.

## SUMMARY OF THE INVENTION

Surprisingly, it has been found that it is possible to obtain a cellulosic textile fabric having a strongly reduced tendency to pilling formation at a significantly reduced weight 25 loss by subjecting the fabric to a biopolishing process, preferably using monocomponent cellulases.

Accordingly, the method of the invention comprises treating a cellulose-fibre-containing textile fabric with a cellulase capable of performing a partial hydrolysis of the fibre sur30 face corresponding to a weight loss of less than 2 w/w%, ba-

3

sed on the untreated cellulosic textile fabric, or corresponding to a weight loss of less than about 2%, calculated as the difference, in terms of percentage, of the weight loss of the cellulase treated textile fabric and the weight loss of the textile fabric treated without cellulase (blank).

## DETAILED DESCRIPTION OF THE INVENTION

#### The fabric

In the present context, the terms "cellulosic textile fabric" and "cellulose-fibre-containing textile fabric" are intended 10 to indicate any type of fabric, in particular woven or knitted fabric, prepared from a cellulose-containing material, containing cellulose or cellulose derivatives, e.g. from wood pulp, and cotton. Also, in the present context, the term "fabric" is intended to include garments and other types of pro-15 cessed fabrics. Examples of cellulosic textile fabric is cotton, viscose (rayon); lyocell; flax (linen); all blends of viscose, cotton or lyocell with other fibers such as polyester; viscose/cotton blends, lyocell/cotton blends, viscose/wool blends, lyocell/wool blends, cotton/wool blends; flax 20 (linen), ramie and other fabrics based on cellulose fibers, including all blends of cellulosic fibers with other fibers such as wool, polyamide, acrylic and polyester fibers, e.g. viscose/cotton/polyester blends, wool/cotton/polyester blends, flax/cotton blends etc.

25 In the present context, the term "strongly reduced tendency to pilling formation" is intended to mean a permanent (and excellent) resistance to formation of pills on the surface of the treated (biopolished) fabric surface in comparison with fabric which has not been subjected to the method of the present invention. The tendency to pilling formation may be tested according to the Swiss norm SN 198525, published in 1990 by Schweizerische Normen-Vereinigung, Kirchenweg 4, Postfach,

4

CH-8032 Zürich, Switzerland, which describes a test of pilling-resistance for textiles which in turn is based on the Swiss norms SNV 95 150 (Textiles - Standard climatic conditions and test conditions for the physical tests under standard climate conditions) and SN 198 529 (Testing of textiles - "Scheuerfestigkeit" - Martindale method). The results of the test is expressed in terms of "pilling notes" which is a rating on a scale from pilling note 1 (heavy pill formation) to pilling note 5 (no or very little pill formation), allowing ½ pilling notes.

In a preferred embodiment of the present invention, the method provides a textile fabric preferably having a pilling note of at least 4, more preferably of at least 4.5, especially of 5, measured according to SN 198525 (1990).

15 In another preferred embodiment, the method of the invention provides a textile fabric having rating which is at least 1, preferably at least 2, especially at least 3, pilling note(s) higher than of the corrsponding untreated textile fabric; the absolute pilling notes being measured according to SN 198525 20 (1990).

According to the method of the invention, the partial hydrolysis of the fibre surface corresponds to a weight loss of less than about 2 w/w%, preferably a weight loss of less than about 1.8 w/w%, more preferably of less than about 1.5 w/w%.

25 The weight loss is determined under controlled conditions, i.e. according to SNV 95150, vide supra. The weight loss is expressed as the difference, in terms of percentage, of the weight loss of the cellulase treated textile fabric and the weight loss of the textile fabric treated without cellulase 30 (blank).

## The process

As mentioned above, cellulase treatment of the fabric may be carried out simultaneously with other fabric manufacturing procedures, e.g. desizing, or after the bleaching of the fabric.

5 It is to be understood that the method of the invention can be carried out in any conventional wet textile processing step, preferably after the desizing or bleaching of the textile fabric, either simultanously with a conventional (wellknown) process step or as an additional process step. The 10 method will typically be accomplished in high-speed circular systems such as jet-overflow dyeing machines, high-speed winches and jiggers. An example of a useful High-speed system is the "Aero 1000" manufactured by Biancalani, Italy. Alternatively, the method can be accomplished in a two-step biopolish-15 ing process, e.g. as disclosed in the International Patent Application published as WO 93/20278, wherein the first step is a separate cellulase treatment which is carried out essentially without mechanical treatment, and followed by a second step wherein the fabric is subjected to a mechanical treat-20 ment. This cellulase treatment can be carried out in a J-Box, on a Pad-Roll or in a Pad-Bath.

Cellulase treatment according to the present invention and desizing are reconcilable processes that can be conducted at the same conditions, i.e. pH, temperature, dosage/time ratio, etc. By performing these processes simultaneously, the overall fabric manufacturing process becomes shortened. Such time saving arrangements are a major benefit of the process of the invention.

Enzyme dosage greatly depends on the enzyme reaction time,
30 i.e. a relatively short enzymatic reaction time necessitates
a relatively increased enzyme dosage, and vice versa. In general, enzyme dosage may be stipulated in accordance with the
reaction time available. In this way cellulase treatment of
the fabric according to the present invention can be brought

6

into conformity with e.g. the desizing conditions, if for instance these two reactions are to be carried out simultaneously.

An enzyme dosage/time ratio similar to what is known from 5 conventional biopolishing may be used. Preferred enzyme dosages are from about 100 to about 100,000 ECU/kg fabric, more preferably from about 500 to about 20,000 ECU/kg fabric, especially from about 1000 to about 5,000 ECU/kg fabric.

Typically, the reaction time is from about 10 minutes to about 4 hours, preferably from about 20 minutes to about 2 hours but the reaction can be carried out for any period of time between about 1 minute and about 24 hours, in dependence of the specific type of processing equipment.

The method of the invention may be carried out in the presentic of certain components which can be added to the cellulase, i.e. the formulated cellulase composition, or separately to the wash liquor wherein the enzyme treatment takes place. Examples of such components include a stabilizer, a wetting agent, a buffer and a dispersing agent. The stabilizer may be an agent stabilizing the cellulolytic enzyme.

The wetting agent serves to improve the wettability of the fibre whereby a rapid and even desizing may be obtained. The wetting agent is preferably of an oxidation stable type.

The buffer may suitably be a phosphate, borate, citrate, ace25 tate, adipate, triethanolamine, monoethanolamine, diethanolamine, carbonate (especially alkali metal or alkaline earth
metal, in particular sodium or potassium carbonate, or ammonium and HCl salts), diamine, especially diaminoethane, imidazole, or amino acid buffer. Preferably, the buffer is a
30 mono-, di-, or triethanolamine buffer.

The dispersing agent may suitably be selected from nonionic,

anionic, cationic, ampholytic or zwitterionic surfactants. More specifically, the dispersing agent may be selected from carboxymethylcellulose, hydroxypropylcellulose, alkyl aryl sulphonates, long-chain alcohol sulphates (primary and secon-5 dary alkyl sulphates), sulphonated olefins, sulphated monoglycerides, sulphated ethers, sulphosuccinates, sulphonated methyl ethers, alkane sulphonates, phosphate esters, alkyl isothionates, acyl sarcosides, alkyl taurides, fluorosurfactants, fatty alcohol and alkylphenol condensates, fatty acid 10 condensates, condensates of ethylene oxide with an amine, condensates of ethylene oxide with an amide, block polymers (polyethylene glycol, polypropylene glycol, ethylene diamine condensed with ethylene or propylene oxide), sucrose esters, sorbitan esters, alkyloamides, fatty amine oxides, ethoxyla-15 ted monoamines, ethoxylated diamines, ethoxylated polyamines, ethoxylated amine polymers and mixtures thereof.

Preferably, the dispersing agent is an ethoxylated fatty acid ester or a nonylphenyl polyethyleneglycol ether.

Further, the method of the invention may be carried out in the presence of a conventional antiredepostion agent, e.g. polymeric agents such as polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), and polyacrylates.

### The enzyme

In the present context, the term "cellulase" or "cellulolytic 25 enzyme" refers to an enzyme which catalyses the degradation of cellulose to glucose, cellobiose, triose and other cello-oligosaccharides.

In the present context the term "enzyme" or "cellulase enzyme" is understood to include a mature protein or a precursor form thereof as well to a functional fragment thereof which essentially has the activity of the full-length enzyme. Furthermore, the term "enzyme" is intended to include homologues

or analogues of said enzyme. Such homologues comprise an amino acid sequence exhibiting a degree of identity of at least 60% with the amino acid sequence of the parent enzyme, i.e. the parent cellulase. The degree of identity may be determined by conventional methods, see for instance, Altshul et al., Bull. Math. Bio. 48: 603-616, 1986, and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff, supra.

Alternatively, the homologue or analogue of the enzyme may be one encoded by a nucleotide sequence hybridizing with an oligonucleotide probe prepared on the basis of the nucleotide sequence or an amino acid sequence under the following conditions: presoaking in 5 X SSC and prehydbridizing for 1 hr. at about 40°C in a solution of 20% formamide, 5 X Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 µg denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100 µM ATP for 18 hrs. at about 40°C, followed by a wash in 0.4 X SSC at a temperature of about 45°C.

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using standard detection pro-25 cedures (e.g. Southern blotting).

Homologues of the present enzyme may have one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding or activity of the protein, small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a po-

9

ly-histidine tract, an antigenic epitope or a binding domain. See in general Ford et al., Protein Expression and Purification 2: 95-107, 1991. Examples of conservative substitutions are within the group of basic amino acids (such as arginine, 1ysine, histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, valine), aromatic amino acids (such as phenylalanine, tryptophan, tyrosine) and small amino acids (such as gly10 cine, alanine, serine, threonine, methionine).

It will be apparent to persons skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active enzyme. Amino acids essential to the activity of the enzyme of 15 the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-1085, 1989). In the latter technique mutations are introdu-20 ced at every residue in the molecule, and the resultant mutant molecules are tested for cellulolytic activity to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined 25 by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labelling. See, for example, de Vos et al., <u>Science</u> <u>255</u>: 306-312, 1992; Smith et al., <u>J. Mol.</u> Biol. 224: 899-904, 1992; Wlodaver et al., FEBS Lett. 309: 59-64, 1992.

The homologue may be an allelic variant, i.e. an alternative form of a gene that arises through mutation, or an altered enzyme encoded by the mutated gene, but having substantially the same activity as the enzyme of the invention. Hence mutations can be silent (no change in the encoded enzyme) or may sencode enzymes having altered amino acid sequence.

10

WO 96/17994 PCT/DK95/00488

The homologue of the present enzyme may also be a genus or species homologue, i.e. an enzyme with a similar activity derived from another species.

A homologue of the enzyme may be isolated by preparing a gen5 omic or cDNA library of a cell of the species in question,
and screening for DNA sequences coding for all or part of the
homologue by using synthetic oligonucleotide probes in accordance with standard techniques, e.g. as described by Sambrook
et al., Molecular Cloning: A Laboratory Manual, 2nd. Ed. Cold
10 Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989,
or by means of polymerase chain reaction (PCR) using specific
primers as described by Sambrook et al., supra.

Preferably, the cellulolytic enzyme to be used in the method of the invention is a monocomponent (recombinant) cellulase, i.e. a cellulase essentially free from other proteins or cellulase proteins. A recombinant cellulase component may be cloned and expressed according to standard techniques conventional to the skilled person.

In a preferred embodiment of the invention, the cellulase to 20 be used in the method is an endoglucanase (EC 3.2.1.4), preferably a monocomponent (recombinant) endoglucanase.

Preferably, the cellulase is a microbial cellulase, more preferably a bacterial or fungal cellulase. Examples of bacterial cellulases are cellulases derived from or producible 25 by bacteria from the group of genera consisting of *Pseudomo*nas or *Bacillus lautus*.

The cellulase or endoglucanase may be an acid, a neutral of an alkaline cellulase or endoglucanase, i.e. exhibiting maximum cellulolytic activity in the acid, neutral of alkaline 30 range, respectively.

Accordingly, a useful cellulase is an acid cellulase, pre-

11

ferably a fungal acid cellulase, more preferably a fungal acid cellulase enzyme with substantial cellulolytic activity at acidic conditions which is derived from or producible by fungi from the group of genera consisting of Trichoderma, 5 Actinomyces, Myrothecium, Aspergillus, and Botrytis.

A preferred useful acid cellulase is derived from or producible by fungi from the group of species consisting of Trichoderma viride, Trichoderma reesei, Trichoderma longibrachiatum, Myrothecium verrucaria, Aspergillus niger, Aspergillus oryzae, and Botrytis cinerea.

Another useful cellulase or endoglucanase is a neutral or alkaline cellulase, preferably a fungal neutral or alkaline cellulase, more preferably a fungal alkaline cellulase or endoglucanase with substantial cellulolytic activity at alkaline conditions which is derived from or producible by fungi from the group of genera consisting of Aspergillus, Penicillium, Myceliophthora, Humicola, Irpex, Fusarium, Stachybotrys, Scopulariopsis, Chaetomium, Mycogone, Verticillium, Myrothecium, Papulospora, Gliocladium, Cephalosporium and

A preferred alkaline cellulase is derived from or producible by fungi from the group of species consisting of Humicola insolens, Fusarium oxysporum, Myceliopthora thermophile, or Cephalosporium sp., preferably from the group of species consisting of Humicola insolens, DSM 1800, Fusarium oxysporum, DSM 2672, Myceliopthora thermophile, CBS 117.65, or Cephalosporium sp., RYM-202.

A preferred example of a native or parent cellulase is an alkaline endoglucanase which is immunologically reactive with 30 an antibody raised against a highly purified ~43kD endoglucanase derived from Humicola insolens, DSM 1800, or which is a derivative of the ~43kD endoglucanase exhibiting cellulase activity. A preferred endoglucanase component has the amino

12

acid sequence enclosed as SEQ ID No. 1 which is also disclosed in the International Patent Application published as WO 91/17243, SEQ ID#2, which is hereby incorporated by reference. Another preferred endoglucanase component is the core enzyme corresponding to the amino acid sequence enclosed as SEQ ID No. 1, but having the amino acid sequence corresponding to position 1-213, i.e. truncated at position 213. It is contemplated that other useful endoglucanases are enzymes having amino acid sequences corresponding to the amino acid sequence enclosed as SEQ ID No. 1, but which are truncated, preferably genetically truncated, at any position between position 213 and position 247 of the SEQ ID No. 1, i.e. having an amino acid sequence consisting of between 213 and 247 amino acid residues.

- other examples of useful cellulases are variants having, as a parent cellulase, a cellulase of fungal origin, e.g. a cellulase derivable from a strain of the fungal genus Humicola, Trichoderma or Fusarium. For instance, the parent cellulase may be derivable from a strain of the fungal species H. inso-
- 20 lens, Trichoderma reesei or F. oxysporum, preferably the -43kD endoglucanase derived from Humicola insolens, DSM 1800, or is a functional analogue of any of said parent cellulases which
- i) comprises an amino acid sequence being at least 60% homo 25 logous with the amino acid sequence of the parent cellulase,
   ii) reacts with an antibody raised against the parent cellulase,
   and/or
  - iii) is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding the parent cellulase.
- 30 Property i) of the analogue is intended to indicate the degree of identity between the analogue and the parent cellulase indicating a derivation of the first sequence from the second. In particular, a polypeptide is considered to be homologous to the parent cellulase if a comparison of the respect-

13

about 60%, such as above 70%, 80%, 85%, 90% or even 95%. Sequence comparisons can be performed via known algorithms, such as the one described by Lipman and Pearson (1985).

The additional properties ii) and iii) of the analogue of the parent cellulase may be determined as follows:

Property ii), i.e. the immunological cross reactivity, may be assayed using an antibody raised against or reactive with at least one epitope of the parent cellulase. The antibody, which may either be monoclonal or polyclonal, may be produced to by methods known in the art, e.g. as described by Hudson et al., 1989. The immunological cross-reactivity may be determined using assays known in the art, examples of which are Western Blotting or radial immunodiffusion assay, e.g. as described by Hudson et al., 1989.

- The oligonucleotide probe used in the characterization of the analogue in accordance with property iii) defined above, may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the parent cellulase. The hybridization may be carried out under any suitable conditions allowing the DNA sequences to hybridize. For instance, such conditions are hybridization under specified conditions, e.g. involving presoaking in 5xSSC and prehybridizing for 1h at ~40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium phosphate, pH 6.8, and 50μg of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100μM ATP for 18h at ~40°C,
- Examples of useful cellulase variants are variants of the 43 kD endoglucanase derived from or producible by Humicola inso30 lens, DSM 1800, SEQ ID NO:1, modified by substitution of one or more amino acid residues in one or more of the positions 8, 55, 58, 62, 67, 132, 147, 162, 221, 222, 223, 280; and optionally further modified by truncation, preferably geneti-

or other methods described by e.g. Sambrook et al., 1989.

14

cally truncation, at any position from position 213.

Preferred cellulase variants are variants of the 43 kD endoglucanase derived from or producible by *Humicola insolens*, DSM 1800, SEQ ID NO:1, modified by substitution of one or more 5 amino acid residues as follows:

Y8F

S55E/D

D58A/S/N

W62E

10 D67R/N

F132A/D/E/G

Y147S

A162P

V221S

15 N222S

Q223T

Y280F.

Surprisingly, it has been found that, in case of using an alkaline endoglucanase such as the 43 kD H. insolens, DSM 20 1800, endoglucanase or the mentioned modified variants thereof, it may be advantageous to carry out the method of the present invention at a pH below about 9, preferably at a pH below 6, more preferably at a pH of from about 4.5 to about 5.5, especially at a pH of about 5.0.

- 25 In the context of this invention, cellulase activity can be expressed in ECU. Cellulolytic enzymes hydrolyse CMC, thereby increasing the viscosity of the incubation mixture. The resulting reduction in viscosity may be determined by a vibration viscosimeter (e.g. MIVI 3000 from Sofraser, France).
- 30 Determination of the cellulolytic activity, measured in terms of ECU, may be determined according to the following analysis method (assay): The ECU assay quantifies the amount of cata-

15

lytic activity present in the sample by measuring the ability of the sample to reduce the viscosity of a solution of carboxy-methylcellulose (CMC). The assay is carried out at 40°C; pH 7.5; 0.1M phosphate buffer; time 30 min; using a relative enzyme standard for reducing the viscosity of the CMC(carboxymethylcellulose Hercules 7 LFD) substrate; enzyme concentration approx. 0.15 ECU/ml. The arch standard is defined to 8200 ECU/g.

Although the useful cellulase may be used as such in the met10 hod of the present invention, it is preferred that it is formulated into a suitable composition. Thus, the useful cellulase may be used in the form of a granulate, preferably a
non-dusting granulate, a liquid, in particular a stabilized
liquid, a slurry, or in a protected form. Dust free granu15 lates may be produced, e.g. as disclosed in US 4,106,991 and
US 4,661,452 (both to Novo Nordisk A/S) and may optionally be
coated by methods known in the art.

Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as e.g. propylene glycol, a sugar or sugar alcohol or acetic acid, according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238 216.

The performance of enzymes greatly depends on process conditions such as e.g. pH and temperature. In accomplishing the process of this invention, of course, factors such as e.g. pH-dependent performance and thermal stability should be taken into consideration in the choice of cellulytic enzymes. Other conditions such as e.g. the addition of wetting agents, etc., also depend on the overall process to be performed, as well as the enzyme employed.

The invention is further illustrated by the following nonlimiting example.

#### **EXAMPLE**

## Apparatus:

The test was carried out in an Atlas LP2 Launder-O-Meter using 2 swatches per beaker.

#### 5 Textile:

Bleached interlock knitted 100% cotton fabric,  $205 \text{ g/m}^2$ . The fabric was cut into pieces of a size 14x12 cm (about 3.5 g each) and conditioned overnight at  $20^{\circ}\text{C}$  and 65% relative humidity under constant conditions.

#### 10 Enzymes:

- A: Reference (Cellusoft L, a commercial acid cellulase preparation produced and sold by Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark).
- B: 43 kD endoglucanase from Humicola insolens, DSM 1800.
- 15 C: Variant of B (substitution D58A)
  - D: Variant of B (substitution F132D)
  - E: Variant of B (substitution Y280F)
  - F: Variant of B (substitution D67R)
  - G: Variant of B (substitution Y147S)
- 20 H: Variant of B (substitution S55E)
  - J: Variant of B (substitutions Y8F, W62E, A162P, V221S, N222S, Q223T)
  - K: Variant of B (substitution Y147N)

## Experimental conditions:

- 25 (Launder-O-Meter biopolishing)
  - 4 beakers (8 swatches) were used for each test.

Liquor ratio 1:20
Liquor volume 140 ml

Abrasive agent 20 steel balls (d=14mm,11g)

5.0

17

рН

Buffer 1 g/l acetate

Time 60 min

Temperature 55°C

## 5 Inactivation:

Each test was terminated by washing all the swatches at 70°C followed by rinsing three times in a standard European home laundry machine, AEG Öko-Lavamat 665.

#### Drying:

10 The swatches were air dried and conditioned overnight at 20°C and 65% relative humidity.

#### Tests:

The commercial enzyme preparation A was tested in 4 dosages in the range 0-4.0~w/w, based on the weight of the textile.

15 Each of the enzyme preparations B-K were tested in 4 dosages in the range 0-5.0 ECU/g textile.

#### Results:

The following parameters were measured/calculated:

- \* Weight loss, in terms of percentage, of the weight loss of the cellulase treated textile fabric and the weight loss of the textile fabric treated without cellulase (blank).
  - \* Pilling note (PN), measured according to SN 198525 (1990) using a Martindale Pilling Tester at 500 revolutions.

The pilling note of the untreated textile as well as of the 25 textile treated without cellulase (blank) was 1.

The following table shows the measured weight loss corresponding to a resulting pilling note of 4.5 of the cellulase treated textile.

TABLE

| 5  | Enzyme   | Weight loss (Δ%) |
|----|----------|------------------|
|    | A (ref.) | 5.6              |
|    | В        | 2.0              |
|    | С        | 1.3              |
|    | D        | 1.3              |
| 10 | E        | 2.0              |
|    | F        | 1.7              |
|    | G        | 1.2              |
|    | Н        | 1.0              |
|    | J        | 1.2              |
| 15 | К        | 1.5              |

19

## SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

- (i) APPLICANT: NOVO NORDISK A/S
- (ii) TITLE OF INVENTION: A Method of Obtaining a Cellulosic Textile Fabric with Reduced Tendency to Pilling Formation
  - (iii) NUMBER OF SEQUENCES: 1
    - (iv) CORRESPONDENCE ADDRESS:
      - (A) ADDRESSEE: NOVO NORDISK A/S, Corporate Patents
        - (B) STREET: Novo Alle
        - (C) CITY: Bagsvaerd
        - (E) COUNTRY: DENMARK
        - (F) ZIP: DK-2880

20

15

- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- 25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
  - (2) INFORMATION FOR SEQ ID NO:1:

30

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 305 amino acids
  - (B) TYPE: amino acid
- 35 (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein

20

- (A) ORGANISM: Humicola insolens
- (B) STRAIN: DSM 1800

## 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala Ala Leu Pro -21 -20 -15 -10

Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys
10 -5 1 5 10

Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val Asn Gln Pro 15 20 25

15 Val Phe Ser Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp Phe Asp Ala 30 35 40

Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys Ala Asp Gln
45 50 55

20

Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe Ala Ala Thr 60 65 70 75

Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala Cys Tyr Glu 25 80 85 90

Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Val Val Gln
95 100 105

30 Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Asn 110 115 120

Ile Pro Gly Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Pro Gln Phe 125 130 135

35

Gly Gly Leu Pro Gly Gln Arg Tyr Gly Gly Ile Ser Ser Arg Asn Glu 140 145 150 155

Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr Trp Arg Phe 40 160 165 170

21 .

|     | Asp        | Trp        | Phe        | Lув<br>175 | Asn        | Ala        | Asp        | naA        | Pro<br>180 | Ser        | Phe        | Ser        | Phe                | Arg<br>185 | Gln        | Val        |
|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------------|------------|------------|------------|
| 5   | Gln        | Сув        | Pro<br>190 | Ala        | Glu        | Leu        | Val        | Ala<br>195 | Arg        | Thr        | Gly        | Сув        | <b>A</b> rg<br>200 | Arg        | Asn        | Авр        |
|     | Авр        | Gly<br>205 | Asn        | Phe        | Pro        | Ala        | Val<br>210 | Gln        | Ile        | Pro        | Ser        | Ser<br>215 | Ser                | Thr        | Ser        | Ser        |
| 10  | Pro<br>220 | Val        | Asn        | Gln        | Pro        | Thr<br>225 | Ser        | Thr        | Ser        | Thr        | Thr<br>230 | Ser        | Thr                | Ser        | Thr        | Thr<br>235 |
| • - | Ser        | Ser        | Pro        | Pro        | Val<br>240 |            | Pro        | Thr        | Thr        | Pro<br>245 | Ser        | Gly        | Сув                | Thr        | Ala<br>250 | Glu        |
| 15  | Arg        | Trp        | Ala        | Gln<br>255 | Сув        | Gly        | Gly        | Asn        | Gly<br>260 | Trp        | Ser        | Gly        | Сув                | Thr<br>265 | Thr        | Сув        |
| 20  | Val        | Ala        | Gly<br>270 |            | Thr        | Сув        | Thr        | Lys<br>275 |            | Двņ        | Asp        | Trp        | Tyr<br>280         | His        | Gln        | Сув        |

Leu

22

#### CLAIMS

- 1. A method for obtaining a cellulosic textile fabric having a strongly reduced tendency to pilling formation, the method comprising treating a cellulose-fibre-containing textile fastric with a cellulase (cellulolytic enzyme) capable of performing a partial hydrolysis of the fibre surface corresponding to a weight loss of less than 2 w/w% based on the untreated cellulosic textile fabric.
- 2. A method according to claim 1, wherein the pilling forma-10 tion corresponds to a pilling note of at least 4, more preferably of at least 4.5.
- 3. A method according to claim 1 or 2, wherein the textile fabric contains cellulose fibres selected from the group consisting of cotton, viscose (rayon), lyocell; all blends of viscose, cotton or lyocell with other fibers such as polyester; viscose/cotton blends, lyocell/cotton blends, viscose/wool blends, lyocell/wool blends, cotton/wool blends; flax (linen), ramie and other fabrics based on cellulose fibers, including all blends of cellulosic fibers with other fibers such as wool, polyamide, acrylic and polyester fibers, e.g. viscose/cotton/polyester blends, wool/cotton/polyester blends, and flax/cotton blends.
- 4. A method according to any of the claims 1-3, wherein the cellulase is a monocomponent cellulase, preferably an endog-25 lucanase (EC 3.2.1.4).
  - 5. A method according to claim 3 or 4, wherein the cellulase is a microbial cellulase, preferably a bacterial or fungal cellulase, more preferably a fungal cellulase.

- 6. The method according to claim 5, wherein the cellulase is an acid cellulase, preferably a fungal acid cellulase, more preferably a fungal acid cellulase with substantial cellulolytic activity at acidic conditions which is derived from or producible by fungi from the group of genera consisting of Trichoderma, Actinomyces, Trichoderma, Myrothecium, Aspergillus, and Botrytis.
- 7. The method according to claim 6, wherein the cellulase is derived from or producible by fungi from the group of species 10 consisting of Trichoderma viride, Trichoderma longibrachiatum, Myrothecium verrucaria, Aspergillus niger, Aspergillus oryzae, and Botrytis cinerea.
- 8. The method according to claim 5, wherein the cellulase is a neutral or alkaline cellulase, preferably a fungal neutral 15 or alkaline cellulase, more preferably a fungal alkaline cellulase with substantial cellulolytic activity at alkaline conditions which is derived from or producible by fungi from the group of genera consisting of Aspergillus, Penicillium, Myceliophthora, Humicola, Irpex, Fusarium, Stachybotrys, Scopulariopsis, Chaetomium, Mycogone, Verticillium, Myrothecium, Papulospora, Gliocladium, Cephalosporium and Acremonium.
- 9. The method according to claim 8, wherein the alkaline cellulase is derived from or producible by fungi from the group of species consisting of Humicola insolens, Fusarium oxyspotrum, Myceliopthora thermophila, or Cephalosporium sp.
- 10. The method according to claim 9, wherein the cellulase is derived from or producible by fungi from the group of species consisting of Humicola insolens, DSM 1800, Fusarium oxysporum, DSM 2672, Myceliopthora thermophila, CBS 117.65, or 30 Cephalosporium sp., RYM-202.
  - 11. The method according to any of the claims 8-10, wherein the treatment is carried out at a pH below about 9, pre-

24

ferably at a pH below 6, more preferably at a pH of from about 4.5 to about 5.5, especially at a pH of about 5.0.

- 12. The method according to claim 10 or 11, wherein the cellulase is a 43 kD endoglucanase derived from or producible by 5 Humicola insolens, DSM 1800, SEQ ID NO:1, or a functional analogue of said cellulase which
  - i) comprises an amino acid sequence being at least 60% homologous with the amino acid sequence of the cellulase,
- ii) reacts with an antibody raised against the cellulase, 10 and/or
  - iii) is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding the cellulase.
- 13. The method according to claim 12, wherein the cellulase is a variant of the 43 kD endoglucanase derived from or pro15 ducible by Humicola insolens, DSM 1800, SEQ ID NO:1, modified by substitution of one or more amino acid residues in one or more of the positions 8, 55, 58, 62, 67, 132, 147, 162, 221, 222, 223, 280; or modified by truncation, preferably genetically truncation, at any position from position 213.

25

14. The method according to claim 12, wherein one or more the amino acid residues are substituted as follows

Y8F

S55E/D

5 D58A/S/N

W62E

D67R/N

F132A/D/E/G

Y147S

10 A162P

V221S

N222S

Q223T

Y280F.

- 15 15. The method according to claim 5, wherein the bacterial cellulase is derived from or producible by bacteria from the group of genera consisting of *Pseudomonas* or *Bacillus lautus*.
- 16. The method according to any of the preceding claims, wherein the treatment is carried out in any wet processing 20 stage of a conventional textile fabric manufacturing process.
  - 17. The method according to claim 16, wherein the treatment is accomplished in high-speed circular systems such as jet-overflow dyeing machines (jet-dyer), high-speed winches and jiggers
- 25 18. The method according to claim 16, wherein the treatment is accomplished in a J-Box, on a Pad-Roll or in a Pad-Bath during a two-step biopolishing process.

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 95/00488

|  |   | PCT/DK 95/   | 700488                   |  |  |  |  |
|--|---|--|--------------------------|--|--|--|--|
| A. CLAS  | SIFICATION OF SUBJECT MATTER  |  |                          |  |  |  |  |
| IPC6: D06M 16/00, C12N 9/42 According to International Patent Classification (IPC) or to both national classification and IPC  |   |  |                          |  |  |  |  |
| _  | o international Patent Classification (IPC) or to both in DS SEARCHED   | national classification and IPC                    |                          |  |  |  |  |
|  | ocumentation searched (classification system followed b   | y classification symbols)                          | ·                        |  |  |  |  |
|  | IPC6: D06M, C12N  |  |                          |  |  |  |  |
| Documental   | tion searched other than minimum documentation to th  | e extent that such documents are included          | l in the fields searched |  |  |  |  |
| SE,DK,FI,NO classes as above   |   |  |                          |  |  |  |  |
| Electronic d   | ata base consulted during the international search (nam   | ne of data base and, where practicable, sea        | rch terms used)          |  |  |  |  |
| WPI, IF  | IPAT, CA  |  |                          |  |  |  |  |
|  | MENTS CONSIDERED TO BE RELEVANT   |  |                          |  |  |  |  |
| Category*  | Citation of document, with indication, where ap   | propriate, of the relevant passages                | Relevant to claim No.    |  |  |  |  |
| X  | WO 9412578 A1 (NOVO NORDISK A/S)<br>(09.06.94)  | ), 9 June 1994                                     | 1-12,15-18               |  |  |  |  |
| ļ  |   |  |                          |  |  |  |  |
| x  | WO 9313261 A1 (GENENCOR INT. INC<br>(08.07.93)  | 1-12,15-18   |                          |  |  |  |  |
|  | <del></del>   |  |                          |  |  |  |  |
| A  | Dialog Information Services, Tex<br>Digest, Dialog Accession no.<br>Cotton Grower: "Putting the<br>fabric", 27, No. 7: 20-21 (C | 1-18   |                          |  |  |  |  |
|  |   |  |                          |  |  |  |  |
|  |   |  |                          |  |  |  |  |
| Further documents are listed in the continuation of Box C. X See patent family annex.  |   |  |                          |  |  |  |  |
| * Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance.  "T" later document published after the international fiting date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention   |   |  |                          |  |  |  |  |
| to be of particular relevance  "E" erlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other  "A" document of particular relevance: the claimed inventon cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |   |  |                          |  |  |  |  |
| special reason (as specified)  "O" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations.   |   |  |                          |  |  |  |  |
| "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family   |   |  |                          |  |  |  |  |
| Date of the  | actual completion of the international search   | Date of mailing of the international 1 4 -03- 1996 | search report            |  |  |  |  |
| 6 March  |   | degi eu e  |                          |  |  |  |  |
| Name and   | mailing address of the ISA/   | Authorized officer                                 |                          |  |  |  |  |
|  | Patent Office<br>S-102 42 STOCKHOLM   | Gerd Strandell                                     | ł                        |  |  |  |  |
|  | lo. + 46 8 666 02 86  | Telephone No. +46 8 782 25 00                      |                          |  |  |  |  |
| •  | A/210 (second sheet) (July 1992)  |  |                          |  |  |  |  |

## INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/96

International application No.
PCT/DK 95/00488

| Patent document cited in search report |         | Publication date | Patent family Publication member(s) date |  | Publication<br>date              |
|--|---------|------------------|--|--|----------------------------------|
| WO-A1-                                 | 9412578 | 09/06/94         | NONE                                     |  |                                  |
| WO-A1-                                 | 9313261 | 08/07/93         | CA-A-<br>EP-A-<br>JP-T-                  | 2125989<br>06177 <b>4</b> 6<br>7502790 | 08/07/93<br>05/10/94<br>23/03/95 |

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

| Defects in the images include but are not limited to the items checked: |
|---|
| M BLACK BORDERS   |
| ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES                                 |
| ☐ FADED TEXT OR DRAWING   |
| ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING                                  |
| ☐ SKEWED/SLANTED IMAGES   |
| COLOR OR BLACK AND WHITE PHOTOGRAPHS                                    |
| ☐ GRAY SCALE DOCUMENTS  |
| ☐ LINES OR MARKS ON ORIGINAL DOCUMENT                                   |
| ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY                 |
| OTHER:  |

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.